Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer by Bauernhofer, T et al.
Role of prolactin receptor and CD25 in protection of circulating
T lymphocytes from apoptosis in patients with breast cancer
T Bauernhofer
1, I Kuss
1, U Friebe-Hoffmann
1, AS Baum
1,4, G Dworacki
1, BK Vonderhaar
2 and TL Whiteside*
,1,3
1University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA;
2Basic Research Laboratory, National Cancer Institute, NIH, Bethesda,
MD 20892, USA;
3Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213-1863, USA;
4Department of Psychiatry,
University of Pittsburgh School of Medicine, Pittsburgh, PA 15213-1863, USA
Prolactin (PRL) has been reported to inhibit apoptosis in various cell types and to serve as a cofactor in the upregulation of CD25 on
T cells during activation. We investigated a possible relation between prolactin receptor (PRL-R) or IL-2 receptor alpha (IL-2Ra,
CD25) expression on circulating T lymphocytes and their apoptosis in patients with breast cancer. Peripheral blood mononuclear
cells obtained from 25 patients, 25 normal controls (NC) and three cord blood samples were evaluated for Annexin V binding and
expression of CD95, CD25, and PRL-R on CD3
+ T cells by multicolour flow cytometry. Plasma levels of PRL, sCD95L, and sIL-2R
were determined in patients and controls and related to T-cell apoptosis. The ability of PRL to protect T cells from apoptosis induced
by various agents was also studied. Expression of PRL-R on the surface of T cells was comparable in patients with breast cancer and
NC, but PRL plasma levels in patients were significantly lower (Po0.05). In patients, 18711% (mean7s.d.) of CD3
+ cells bound
Annexin V, compared to 976% in NC (Po0.0004). Percentages of CD3
+Fas
+ and CD3
+CD25
+ cells were higher in the peripheral
circulation of patients than NC (Po0.0001 and o0.04, respectively). Levels of sFasL were lowest in plasma of the patients with the
highest proportions of CD3
+Fas
+ T cells. Most T cells undergoing apoptosis were CD3
+CD25
  in patients, and the proportion of
CD3
+CD25
  Annexin V
+ cells was significantly increased in patients compared to NC (Po0.006). Ex vivo PRL protected T cells from
starvation-induced or anti-CD3Ab-induced but not from Fas/FasL-dependent apoptosis. These results indicate that expression of
CD25 but not of PRL-R on the surface of activated T lymphocytes appears to be involved in modulating Fas/Fas – ligand interactions,
which are, in part, responsible for apoptosis of T lymphocytes and excessive turnover of immune cells in the circulation of patients
with breast cancer.
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Patients with cancer often have dysfunctions of the immune
system (Kiessling et al, 1999; Whiteside, 2001). We have shown
previously that the proportion of circulating T lymphocytes
undergoing apoptosis is significantly higher in patients with
melanoma or head and neck cancer compared to healthy
individuals (Saito et al, 2000; Dworacki et al, 2001; Hoffmann
et al, 2002). Decreased or absent z chain expression in T
lymphocytes and elevated percentages of Fas
+CD3
+ lymphocytes
in the peripheral circulation of patients with solid tumours have
been linked to the increased susceptibility of their T lymphocytes
to ‘spontaneous’ apoptosis (Kuss et al, 1999; Chen et al, 2000;
Dworacki et al, 2001; Hoffmann et al, 2002). However, there is
relatively little information available about the mechanisms
underlying these phenomena in cancer patients or about factors
that could protect the immune cells from spontaneously under-
going programmed cell death.
Several lines of evidence demonstrate that prolactin (PRL), a
peptide hormone, which is synthesised and secreted primarily by
the anterior pituitary gland but also produced in many extra-
pituitary sites, including breast tissue and T lymphocytes, is an
important immunoregulatory factor (Matera, 1996; Bole Feysot
et al, 1998). Prolactin modulates functions of the immune system
by stimulating cell proliferation and prolonging cell survival
(Clevenger et al, 1998). Several in vitro studies have suggested that
exogenous PRL can act as a comitogen for Concanavalin A (Con
A)-stimulated splenocytes (Montgomery et al, 1987), IL-2-stimu-
lated L2 T cells (Clevenger et al, 1990) and human peripheral blood
lymphocytes (Matera et al, 1992). In rat Nb2 T cells, PRL has been
shown to act as a mitogen (Yu Lee, 1990). Porlactin effects are
mediated by the prolactin receptor (PRL-R), a member of the
haematopoietin cytokine receptor superfamily (Bazan, 1989),
which is ubiquitously expressed on immune cells (Dardenne et al,
1994).
The immunomodulatory effects of PRL may be owing to its
ability to induce directly the expression of growth-related genes
(Yu Lee, 1990). Alternatively, PRL could act indirectly by
upregulation of the expression of cytokine receptors, such as IL-
2 receptor alpha (IL-2Ra, CD25) as reported for rat splenocytes Revised 24 October 2002; accepted 22 January 2003
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s(Mukherjee et al, 1990) and for mouse CD4
+ and CD8
+ T cells
(Gala and Shevach, 1993). Prolactin could also upregulate
expression of its own receptor on human peripheral blood
lymphocytes (Dardenne et al, 1994), including T cells (O’Neal
et al, 1991). On the other hand, IL-2 is known to be able to modify
the PRL/PRL-R pathway in T lymphocytes: upon IL-2 activation of
T cells, a rapid translocation of PRL from the cell surface into the
nucleus and of the PRL-R to the nuclear periphery is observed
(Clevenger et al, 1990). One of the less known effects of PRL is the
ability to inhibit apoptosis in various cell types, including the Nb2
rat lymphoma cell line (LaVoie and Witorsch, 1995; Weimann et al,
1999). In addition, evidence exists that human PRL-antagonists,
such as HPRL-G129R, can inhibit cancer cell proliferation through
induction of apoptosis (Chen et al, 1999).
Current evidence suggests that a close relation exists between
PRL-R, IL-2R, and their ligands, which influences cell growth,
activation, and death of immune cells. In this paper, we examine
the possibility that the PRL/PRL-R is involved in protection of
CD3
+ immune cells from apoptosis in patients with breast cancer.
To this end, PRL-R expression on T cells and levels of serum PRL
were examined and correlated with the Annexin V binding and
expression of CD95 and CD25 on these cells in the peripheral
circulation of women with breast cancer and healthy controls.
MATERIALS AND METHODS
Patients
Peripheral blood mononuclear cells (PBMC) were obtained from
25 women with breast cancer, who were followed either at the
Outpatient Clinic of the University of Pittsburgh Cancer Institute
or at Magee Womens Hospital. Peripheral blood mononuclear cells
were also obtained from 25 healthy volunteers as well as three cord
blood samples. The patients and healthy volunteers enrolled in this
study all had signed informed consent forms approved by the IRB
and the IRB for Magee Womens Hospital. Patients included in this
study all had previous surgery and/or other therapies for breast
cancer. They were evaluated at least 3 months (median 13 months)
after the termination of either postoperative radiation and/or
chemotherapy. Some patients (n¼3) and healthy controls (n¼5)
were studied at more than one time point. The patients and
controls were sex- and age-matched, with a mean age7s.d. of
6077 years for the breast cancer patients and 54715 years for the
control group. Patient characteristics are listed in Table 1.
Peripheral blood mononuclear cells
Venous blood (20ml) drawn in lithium heparin tubes was obtained
from the patients and controls. Peripheral blood mononuclear cells
were isolated by Ficoll – Hypaque gradient centrifugation, washed
twice in Dulbecco’s phosphate-buffered saline (D-PBS; Life
Technologies, Inc., Grand Island, NY, USA), counted in a trypan
blue dye, and immediately used for experiments. The time elapsed
between venipuncture and testing was about 3h. The plasma was
aliquoted into vials and stored at  801C for testing of PRL levels.
Cell lines
The human breast cancer cell line T47D and the Jurkat human T-
cell lymphoma cell line were obtained from the ATCC (Manassas,
VA, USA). The two cell lines were maintained in RPMI 1640
medium (Life Technologies) supplemented with 10% (vv
 1) foetal
calf serum (FCS), 1mM glutamine, 100Uml
 1 penicillin, and
100mgml
 1 streptomycin (all from Life Technologies, Inc.). The
T47D cell line was passaged by trypsinisation. Before staining for
PRL-R, T47D cells were detached from plastic using a cell
dissociation solution (Sigma, St Louis, MO, USA). Tests for
mycoplasma (Gen Probe, San Diego, CA, USA) were performed at
monthly intervals and were negative for all cell lines.
Staining of cells for flow cytometry
Prolactin receptor Suspensions of PBMC were prepared contain-
ing 5 10
5cells per 100ml of D-PBS washing buffer supplemented
with 0.1% (wv
 1) sodium azide, and 0.1% (wv
 1) bovine serum
albumin (BSA). The cell suspensions were incubated for 30min at
41C with 1ml of pretitred stock solution (1mgml
 1) of unlabelled,
protein-A purified mouse anti-human PRL-R monoclonal antibody
(mAb), B6.2 (IgG1) described previously (Banerjee et al, 1993).
Mouse IgG1 (DAKO Corp., Carpinteria, CA, USA) was used as an
isotype control. Erythrocytes were then lysed with NH4CL, and the
cells were washed twice and incubated with FITC-conjugated goat
anti-mouse IgG1 F(ab)2 (GAMIg, Caltag, San Francisco, CA, USA)
for 30min at 41C. In chessboard titrations, the optimal concentra-
tion was found to be 10mgml
 1 for the first-step mAb, B6.2, and
50mlml
 1 for the second-step mAb, GAMIg. After two washes, an
excess of mouse IgG1 was added to PBMCs for 15min at room
temperature (RT) to saturate free binding sites on the FITC-
conjugated secondary antibody and to prevent nonspecific
staining. The cells were then incubated with one or two of the
following phycoerythrin (PE)- or PerCP-conjugated anti-human
mAbs: anti-CD3, anti-CD56, or the appropriate IgG1 isotype
control (all purchased from Becton Dickinson, San Jose, CA, USA)
for 30min at 41C. After two washes, the cells were fixed with 0.5%
(wv
 1) paraformaldehyde in D-PBS. All mAbs were pre-titred on
normal PBMCs to determine their optimal dilutions.
In all experiments, cells of each patient were always tested in
parallel with those obtained from a normal control. The T47D
breast cancer cell line was used as a positive control.
Annexin V, CD95, and CD25 Fresh PBMC were washed once in
buffer, divided into aliquots of 5 10
5 cells in 100ml of the same
buffer and incubated in the presence of PE-labelled CD95 mAb
(Clone DX2, PharMingen, San Diego, CA, USA) or PE-labelled
anti-CD25 mAb, PerCP-labelled anti-CD3 mAb or respective
isotype control mAbs (all from Becton Dickinson) for 30min at
41C. After one wash with buffer and with Annexin V-buffer
(PharMingen), the cells were resuspended in 100ml of Annexin V-
buffer and incubated with 1ml of the AnnexinV-FITC conjugate
Table 1 Clinicopathological characteristics of the patients with breast
cancer included in the study
Characteristics Patients (n=25)
Age
median (range; years) 63 (45–76)
Tumor stage at the time of diagnosis
Stage 0 2
Stage 1 15
Stage 2 6
Stage 3 2
Prior treatment
a
Surgery
1 25
Postoperative XRT
2 18
Chemotherapy
3 14
Chemotherapy and XRT
4 8
Disease status at time of blood draw
M0 23
M1 2
Treatment at time of blood draw
Hormonal therapy (tamoxifen) 11
aTermination of prior treatment in months (median) before time of blood draw:
127;
216;
313.5;
413.
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s(PharMingen) for 20min at RT in the dark. Next, an aliquot of
300ml Annexin V-buffer was added to each tube, and the flow
cytometry analysis was performed within the next 60min.
Flow cytometry
Three-colour flow cytometry analysis was performed on a
FACScan (Becton Dickinson, Mountain View, CA, USA) equipped
with a single 488nm argon ion laser. For each sample, at least
10000 events were acquired. The amplification and compensation
were set according to a standard procedure used in our laboratory
and described (Dworacki et al, 2001; Hoffmann et al, 2002). For the
PRL-R determination in PBMC, gates were set on lymphocytes and
backgated on a CD3
+/CD56
  cell population to establish the
relative cell number and arithmetric mean fluorescence intensity
(MFI). The percentage of apoptotic cells was calculated by scoring
Annexin V-binding cells after backgating on CD3
+ cells in the third
colour. All gated mononuclear cell subpopulations were visualised
on forward angle scatter/side angle scatter (FSC/SSC) dot-plots. In
order to include all apoptotic cells and avoid debris with a high
SSC signal, the gate was set to include a wide boundary of
mononuclear cells (‘open gate’), since apoptotic cells accumulated
mainly in the lower FSC/SSC channels (Darzynkiewicz et al, 1992;
Saito et al, 2000; Dworacki et al, 2001). The cutoff for apoptotic
cells was set based on staining of PBMC pretreated with CH-11 Ab
(200ngml
 1; UBI Biotechnology, Lake Placid, NY, USA), using
Annexin V-positive cell population and Annexin V plus PI-positive
population. In the subsequent experiments, apoptotic cells
(Annexin V
+) were quantitated within the CD3
+CD25
+ or
CD3
+CD25
  as well as CD3
+CD95
+ and CD3
+CD95
  cell popula-
tions by three-colour flow cytometry.
Induction of apoptosis in Jurkat cells
Jurkat cells (1 10
6ml
 1) were suspended in RPMI 1640 medium
supplemented with 0.5% charcoal-striped FCS for 24h prior to the
experiments. Apoptosis was induced either by further serum
starvation or by incubation in the presence of CH-11 Ab
(200ngml
 1), 20mM VP-16 (Sigma) or 100nM dexamethasone
(Sigma) with or without the addition of human PRL (20–
200ngml
 1, a gift of Dr Parlow, NHPP, UCLA, Torrance, CA,
USA) for 2, 4, 6, and 24h at 371C. The time course of Annexin V
binding to Jurkat cells was established by flow cytometry
performed as described above.
Activation of PBMC with anti-CD3Ab, IL-2, and PRL
Wells of 96-well plates were coated with anti-CD3Ab (0.5mgml
 1)
in D-PBS at 371C for 90 min and washed three times with D-PBS.
Peripheral blood mononuclear cells obtained from normal donors
were seeded at the concentration of 4 10
5cells per 200ml of AIM-
V medium into each well. Either IL-2 at the concentration of
25IUml
 1 or PRL at the concentration of 20 or 200ngml
 1 or the
combination of IL-2 and PRL were added to the wells. Wells not
coated with anti-CD3Ab and not containing IL-2 or PRL served as
controls. T-cell activation experiments were performed in an
atmosphere of 5% CO2 in air at 371C for 72h. For proliferation
assays, 1mCi of
3H-labelled thymidine was added to each well 18h
before harvesting the cells. Alternatively, the cells were harvested,
washed twice with buffer and stained for Annexin V, PI, CD95,
CD25, CD71, and CD3 as described above.
Measurements of PRL, soluble Fas Ligand (sFasL), and
soluble IL-2 receptor (sIL-2R) in plasma
Blood was drawn between 9 and 12 a.m. from all patients and
controls. Plasma was recovered from whole blood of the sample
collected on the same day as that used for lymphocyte testing
after centrifugation for 10min at 2000r.p.m. and was frozen
immediately at  801C. All tests were performed in a single assay. A
two-side sandwich immunoassay to measure PRL levels was
performed at the Clinical Chemistry Laboratory, UPMC. This
chemoluminescence assay uses constant amounts of two Abs, a
polyclonal goat-anti-human PRL Ab labelled with acrothymium
ester and a mouse-anti-human PRL mAb covalently coupled to
paramagnetic particles, for detection of PRL. A direct relation exits
between PRL present and the amount of relative light units (RLU)
detected by Advia-Centaur analyzer (Bayer, Pittsburgh, PA, USA),
and the RLU are automatically translated into PRL ngml
 1 by the
analyzer.
Soluble FasL was determined by a quantitative sandwich enzyme
immunoassay (Oncogene Research Products, Boston, MA, USA),
employing a mAb specific for the human FasL protein. The lower
limit of detection for sFasL was 0.02ngml
 1.
Soluble IL-2R was quantitated using an enzyme-linked im-
munosorbent assay (Cellfree
s human ELISA sIL-2R, Pierce-
Endogen, Rockford, IL, USA). The assay sensitivity was
o24Uml
 1 sIL-2R.
The procedures for both assays were carried out according to
the protocol provided by the manufacturers.
STATISTICAL ANALYSES
Unpaired two-tailed t-test was used to evaluate differences between
breast cancer patients and normal controls. Linear regression was
employed to examine correlations between all the parameters
studied and age. No correlation of any of the parameters
investigated in this study with age was observed in either patients
or controls. Graphpad Instat software (Version 3.01 for Windows
95/NT, GraphPad Software, San Diego, CA, USA) was used for all
statistical analyses performed.
RESULTS
Prolactin and apoptosis induction in Jurkat cells
In order to test the hypothesis that PRL might be able to inhibit the
onset of apoptosis in T lymphocytes, the Jurkat cell line was used
as a model system. The rationale for selecting Jurkat cells, instead
of PRL-dependent Nb-2 rat lymphoma cell line, was to have a
human model system previously shown to be PRL sensitive
(Matera et al, 1997). Apoptosis was induced in Jurkat cells either
by starvation in RPMI 1640 medium supplemented with 0.5%
charcoal-striped FCS or by treatment of the cells with the Fas
crosslinking CH-11 mAb, dexamethasone, or VP-16 for various
time periods (Figure 1). The apoptosis-inducing agents were added
in the presence or absence of different PRL concentrations (data
not shown). Prolactin at the concentration of 200ngml
 1 was
found to significantly decrease apoptosis induced by serum
starvation (Figure 1A). However, PRL did not prevent the onset
of apoptosis in Jurkat cells treated with CH-11 mAb or VP-16
(Figure 1B, C). Jurkat cells turned out to be insensitive to apoptosis
induced by corticosteroids, and it was not possible to evaluate
effects of PRL on dexamethasone-induced apoptosis. Instead, our
results showed that in the presence of dexamethasone, PRL was no
longer able to prevent starvation-induced apoptosis (data not
shown), confirming previously reported antagonistic effects of
dexamethasone on PRL activity (Clevenger et al, 1998).
Prolactin receptor expression of T lymphocytes and PRL
plasma levels
To evaluate the role of PRL and PRL-R in spontaneous apoptosis of
circulating T cells observed in cancer patients, we measured these
parameters in patients with breast cancer and in normal controls.
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sBy flow cytometry, all circulating CD3
+ T lymphocytes were
positive for PRL-R expression in breast cancer patients as well as
control individuals. The MFI of the PRL-R on T lymphocytes
of breast cancer patients was 56–175 (median 106) compared to
60–176 (median 101) in normal controls, indicating a similar level
of PRL-R expression on T lymphocytes in patients and controls
(Figure 2). Annexin V binding to CD3
+ T cells was then evaluated
in the same cohorts of patients and controls. As shown in Table 2,
a significantly higher proportion of T cells was undergoing
apoptosis in the peripheral circulation of patients than of controls.
Thus, despite the equivalent expression of PRL-R on all circulating
T cells in patients and controls, spontaneous apoptosis was
significantly greater (Po0.0004) in the former.
Since there was a possibility that levels of PRL in the circulation
could influence PRL-R signalling, we next quantitated plasma
levels of PRL in the patients and controls. We found that PRL
plasma levels were significantly lower in patients compared to
normal controls (5.773 vs 8.274ngml
 1; Po0.05). However, no
correlation could be established between Annexin V binding,
signifying the onset of early apoptosis, and PRL-R expression or
PRL plasma levels. In addition, CD25 expression on T cells did not
correlate with either of these parameters.
Fas (CD95) expression and Annexin V-binding
to T lymphocytes
In our previous studies of patients with cancer, CD95
+CD3
+ T cells
accounted for a major proportion of circulating lymphocytes
(Hoffmann et al, 2002). Therefore, flow cytometry was used to
determine the proportion of circulating CD95
+ T lymphocytes in
patients with breast cancer and controls. As shown in Table 2, the
proportion of CD95
+CD3
+ cells was significantly elevated in
patients (Po0.0001) relative to controls. Very few cord blood T
cells expressed Fas. Since Fas expression on T cells could
be responsible for their susceptibility to apoptosis, we next
determined the proportion of Annexin V-binding Fas
+ T cells in
the same specimens. A significantly higher percentage of Fas+ T
cells bound Annexin V in patients than in controls (Po0.0003)
and in cord blood, only 0.570.5% of T cells were Fas
+Annexin V
+
(Table 2). Representative flow cytometry data for a patient
with breast cancer, a control donor, and a cord blood sample
are shown in (Figure 3A – C). The results clearly show that in
patients with breast cancer, Fas
+CD3
+ T cells preferentially bind
Annexin V.
Analyses were next performed to determine whether the extent
of spontaneous T-cell apoptosis could be related to the disease
stage, presence of metastases, or previous therapy in patients with
breast cancer. Interestingly, even in patients with Stage I disease at
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Figure 1 Ex vivo protection of Jurkat cells from apoptosis by exogenous
PRL. Jurkat cells were incubated in the presence or absence of 200ngml
 1
of PRL (A); 200ngml
 1 of CH-11 Ab (B); or 20mM VP-16 (C). Following
incubation for various periods of time, Annexin V binding to Jurkat cells was
measured by flow cytometry as described in Materials and Methods. The
data are presented as means 7s.d. A representative experiment of two
performed is shown.
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Figure 2 A series of flow cytometry histograms showing the expression of the PRL-R on CD3+ T cells (’, Isotype control, &, Prl-R+ CD3 cells).
Virtually all CD3+ T cells are PRL-R positive on the cell surface in PBMC of a typical patient with breast cancer (BC) and a normal control. Three-colour flow
cytometry was performed as described in Materials and Methods.
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sthe time of diagnosis and no evidence of recurrence at the time of
the blood draw, we observed a significantly higher percentage of
circulating T cells binding Annexin V (Table 3) as compared to
normal controls. Also, prior postoperative radiation or adjuvant
chemotherapy did not alter the proportions of apoptotic T cells in
breast cancer patients. It is important to note that the data for
Annexin V binding and CD95 expression were highly consistent in
those normal individuals who were tested more than once. It was
possible to confirm in some cases that the proportions of CD95
+,
Annexin V
+, or CD95
+Annexin V
+ T cells in the peripheral
circulation remained unchanged over a time period of up to 1 year.
In contrast, proportions of Annexin V
+CD95
+CD3
+ T cells were
less stable in patients with breast cancer, as two out of four
patients for whom two serial tests were available had a decreased
and the other two increased proportions of these cells on repeated
examination.
Table 2 Proportions of CD3
+ T cells expressing CD95 and binding Annexin V in PBMC and plasma levels
of sCD95L in patients with breast cancer, normal controls and cord blood
Annexin
V
+ CD3
+(%)
CD95
+
CD3
+ (%)
Annexin V
+
CD95
+ CD3
+ (%)
sCD95L in
plasma (ngml
 1)
Patients (n=25) 18711 67716 15711 0.270.2
Normal controls (n=25) 9764 7 711 775 0.470.3
Cord blood (n=3) 1724 72 0.570.5 1.970.3
P
a 0.0004 0.0001 0.0003 0.007
aThe data are means7s.d. The P-values refer to the difference between the means of normal controls and patients with
breast cancer.
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Figure 3 Expression of CD95 on CD3
+ T cells (A); Annexin V binding to CD3
+ T cells (B) and Annexin V binding to CD95
+ cells (C) in PBMC obtained
from a representative patient with BC, a normal donor, or cord blood. Backgate was set on CD3
+cells. Three-colour flow cytometry was performed as
described in Materials and Methods.
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sSoluble FasL (sCD95L) plasma levels in patients
and controls
In order to attempt to explain the mechanisms responsible for the
higher onset of early apoptosis in CD95
+ T cells in patients with
breast cancer, we next determined plasma levels of sCD95L in the
cohorts of patients and controls. The expectation was that sCD95L
might be utilised in patients through its binding to CD95 expressed
on T cells. Indeed, a statistically significant lower level of sCD95L
was found in patients compared to normal controls and cord
blood, as shown in Table 2. Those breast cancer patients with the
highest percentage of CD95
+ CD3
+ T cells had the lowest sCD95L
levels in the plasma (Figure 4), suggesting increased binding or
utilisation of the sCD95L in these individuals. These results imply
that sCD95L might contribute to apoptosis of CD3
+Fas
+ lympho-
cytes in the circulation of patients with breast cancer.
IL-2 Ra (CD25) expression and Annexin V binding
to T lymphocytes
Similar to Fas expression, CD25 expression is considered to be a
result of T-cell activation. We, therefore, examined CD25
expression on T cells that bind Annexin V in a subgroup of
patients and an age-matched subgroup of normal individuals as
well as in cord blood samples (Table 4). We observed a statistically
significant increase in the percentage of CD25
+ T cells (Po0.04) as
well as in the MFI for CD25 (Po0.02) in CD3
+ lymphocytes of
patients as compared to normal controls. These findings are
consistent with the observed significant increase in the level of sIL-
2R in plasma of the patients (Table 4). An increased proportion of
CD3
+ lymphocytes in patients was found to be Annexin V
+CD25
+
as compared to controls (NSD, Table 4). Unexpectedly, however,
there was a highly statistically significant difference in the
percentage of CD3
+ CD25
  cells that bound Annexin V in patients
as compared to controls (Po0.006). These results suggested that
CD3
+ CD25
  T cells were also targeted for apoptosis in the
circulation of patients with breast cancer. Representative data for
the CD25 expression and Annexin binding by T cells in a patient
with breast cancer, a normal donor, and a cord blood sample are
shown in Figure 5. Importantly, these data demonstrate that in
patients, CD25
  T lymphocytes preferentially bind Annexin V
(Figure 5B).
Ex vivo T-cell activation with anti-CD3Ab or IL-2 in the
presence or absence of PRL
To address the question of whether the state of T-cell activation
could be related to the higher proportions of T lymphocytes
undergoing apoptosis, as seen in patients with breast cancer, we
performed ex vivo experiments, using plastic immobilised anti-
CD3Ab for lymphocyte activation. When normal PBMC were
incubated in wells of 96-well plates coated with anti-CD3Ab with or
without the addition of IL-2, PRL, or the combination of IL-2 and
PRL, a significant increase in proliferation (data not shown) as well
as increased expression of CD95, CD25 (Figure 6), and CD71 on
the surface of T cells was observed after 72h regardless of the
condition used. When Annexin V binding to CD3
+ T cells was
measured in these cultures, twice as many T cells were apoptotic in
cultures containing anti-CD3Ab or anti-CD3Ab+IL-2 compared to
T cells cultured in medium clone. In the presence of PRL,
apoptosis of T cells activated by anti-CD3Ab or anti-CD3Ab+IL-2
was reduced by approximately 40% (Figure 6). These ex vivo
results suggested that PRL could protect T cells from activation-
induced cell death.
DISCUSSION
Spontaneous apoptosis of T lymphocytes or T-cell subsets in the
circulation of patients with solid tumours is a consistently
observed phenomenon (Saito et al, 2000; Dworacki et al, 2001;
Hoffmann et al, 2002). Circulating CD8
+ T lymphocytes appear to
be preferentially targeted for apoptosis (Hoffmann et al, 2002).
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Figure 4 Correlation between sFasL in plasma and expression of Fas on
CD3
+ T cells in the patients with BC and normal controls. The P-value
shown is for combined analysis of patients and controls. When cord blood
samples were included, the P-value was 0.0001.
Table 3 Proportions of T lymphocytes expressing CD95 and binding Annexin V in PBMC of patients with
breast cancer relative to their clinicopathological features, disease stage, and prior or concurrent treatments
CD95+
CD3+ (%)
a
Annexin V+
CD3+ (%)
a
Annexin V+ CD95+
CD3+ (%)
a
All patients (n=25) 67716 18711 15711
M0 (n=23) 70716 18710 15710
M1 (n=2) 87743 5 710 35710
Stage 1 (n=15)
b 66716 16781 4 77
Stage 4 1( n=8) 76716 25710 20711
No XRT (n=7) 75715 13791 1 78
XRT (n=18) 65717 19711 16711
No Chemo (n=11) 63717 17713 15712
Chemo (n=14) 75716 19710 17710
Prior XRT & Chemo (n=8) 77717 22710 19710
No Tamoxifen (n=14) 68720 19713 15714
Tamoxifen (n=11) 65711 17761 4 76
aThe data are means7s.d. XRT=radiation therapy.
bTwo patients with Stage 0 are not included in this analysis.
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sTable 4 Proportions of CD25
+CD3
+Annexin V
+ lymphocytes and MFI of CD25 expression in cord blood
and in PBMC of normal controls and patients with breast cancer
CD25
+ CD3
+
(MFI)
a
Annexin V
+ CD25
+
CD3
+ (%)
a
Annexin V
+ CD25
 
CD3
+ (%)
a
sIL-2Ra
(Uml
 1)
Patients (n=18) 233726 16731 9 711 7617285
Normal controls (n=18) 206723 10758 76 4887166
Cord blood (n=3) 109713 4721 71 8277162
P
b 0.02 0.08 0.006 0.01
aThe data are means7s.d. MFI=mean fluorescence intensity; CD25=IL-2Ra; sIL-2Ra=soluble IL-2Ra.
bThe P-values reflect
comparisons performed between normal controls and breast cancer patients.
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Figure 5 Expression of CD25 on CD3
+ T cells (A) and Annexin V binding to CD25
+ cells (B) in PBMC obtained from a representative patient with BC, a
normal donor, or cord blood. Backgate was set on CD3
+ cells. Three-colour flow cytometry was performed as described in Materials and Methods.
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Figure 6 Ex vivo activation of normal PBMC with anti-CD3Ab (0.5mgml
 1) in the presence or absence of PRL and/or IL-2. After 72h of incubation, the
proportion of Annexin V-binding CD3+ T cells present in culture was determined by multicolour flow cytometry. Representative data from two
experiments preformed are presented as means7s.d.
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sHere, we have demonstrated that in postoperative breast cancer
patients, a significantly higher proportion of CD3
+ T cells bind
Annexin V and express Fas than that in normal age- and sex-
matched controls. The comparison of cord blood samples with
normal controls and breast cancer patients showed clearly that
without Fas expression on T cells, there was essentially no
apoptosis in CD3
+ lymphocytes. As PBMC of both normal donors
and patients with cancer contain antigen-primed T cells, it is not
surprising that expression of Fas is detectable on a substantial
proportion of these T cells.
Clearly, Fas expression is increased in CD3
+ cells experiencing
chronic antigenic stimulation, as is the case in cancer patients,
where Fas expression may be found on virtually all T lymphocytes
(Dworacki et al, 2001; Hoffmann et al, 2002). Nevertheless, Fas
expression alone does not necessarily explain higher levels of T-
cell apoptosis. The sensitivity of these cells to apoptosis may be
influenced by many factors, including the functional state of CD95
(Peter et al, 1997) as well as the presence of FasL necessary for
crosslinking of the receptor (Ju et al, 1995). While the Fas/FasL
pathway appears to participate in inducing apoptosis of CD4+ T
cells in HIV (Badley et al, 1998) and of CD8+ T cells in cancer
(Saito et al, 2000; Dworacki et al, 2001; Hoffmann et al, 2002), it is
clearly not the only mechanism responsible for elimination of
activated T cells. Among other factors that have been suggested are
TNF/TNF-R, TRAIL/TRAIL-R (Srivastava, 2001), tumour-derived
soluble factors (Taylor et al, 2001), and reactive oxygen
metabolites (Hansson et al, 1999; Schmielau and Finn, 2001). In
the case of patients with breast cancer we evaluated, utilisation of
sFasL present in the plasma suggests its engagement in Fas-
mediated apoptosis. The source of sFasL might be the primary or
metastatic breast carcinoma itself. There is evidence in the
literature that breast tumours overexpress FasL on the cell surface
and that this overexpressed FasL is responsible for T-cell apoptosis
(Muschen et al, 2000). Of particular interest was the observation
that even in patients with stage I disease at diagnosis and no
evidence of disease at the time of blood draw, there was a high
proportion of T cells undergoing apoptosis. Similar observations
are emerging in our studies of patients with other solid tumours
(Hoffmann et al, 2002). This suggests that tumor-induced or
tumour-related effects on the haematopoietic system are long
lived. As a result of the small number of patients with advanced
disease and no preoperative patients included in this study, we
could not evaluate a relation between the stage of disease and
magnitude of apoptosis of T lymphocytes. However, the highest
proportion of Annexin V
+Fas
+ T lymphocytes was observed in the
two patients who had metastatic disease at the time of the blood
draw. In aggregate, these observations suggest that activated T cells
are rapidly turning over in patients with breast cancer and that
Fas/FasL interactions may be, in part, responsible for apoptosis of
T cells, leading to their extensive turnover. As such rapid turnover
is likely to result in the paucity of antitumour effector cells, finding
the means of protection of T cells from apoptosis seen in cancer
patients is of great interest. Hence, protective effects of PRL on T-
cell apoptosis were examined.
Prolactin receptor was found to be expressed on all circulating T
cells, and its ligand, PRL, is known to stimulate lymphocyte
proliferation (Montgomery et al, 1987; Clevenger et al, 1990; Yu
Lee, 1990; Matera et al, 1992) and to protect some lymphoid cells
from apoptosis (LaVoie and Witorsch, 1995; Weimann et al, 1999).
In our hands, exogenous PRL was found to offer protection to T
cells from starvation-induced and anti-CD3Ab/IL-2-induced
apoptosis but not from death induced by the Fas crosslinking
antibody, CH-11. This selective protection of T cells from death by
the ubiquitous hormone, PRL, could be envisioned as an attempt
to balance haematologic homeostasis, and we expected to find
higher plasma PRL levels in patients than controls. However, levels
of PRL in plasma were significantly lower in our treated patients
with primary operable breast cancer relative to normal controls.
This counterintuitive finding was further investigated by excluding
premenopausal women from the normal control group for data
analysis. Although this manoeuvre eliminated significance of the
difference in PRL levels between the cohorts, the patients were still
lower than controls. It is possible to speculate that patients have
higher serum levels of PRL-binding protein than controls and that
lower PRL is related to the apparent lack of protection of T cells
from apoptosis in these patients. The observed decreased PRL
serum levels in our cohort of patients could also be a result of
therapy. However, 11 out of 25 patients were treated with
tamoxifen, and it has been shown recently that chronic tamoxifen
treatment does not alter PRL plasma levels in postmenopausal
women with breast cancer (DeMarinis et al, 2000). Furthermore,
no difference in Annexin V binding to T cells binding was
observed between patients who were treated or not treated with
tamoxifen.
Expression of CD25 on CD3
+ T cells appeared to be related to
sensitivity or resistance of the patients’ T cells to apoptosis. A
much higher percentage of patients’ T cells expressed CD25 than
that in normal donors (Figure 6) and the level of CD25 expression/
cell (MFI) was also higher in patients than controls (Table 4).
Surprisingly, our data indicated that expression of CD25 on T cells
in patients with breast cancer tended to protect these cells from
apoptosis and that CD3
+CD25
  cells preferentially bound Annexin
V. Thus, not all circulating T cells were equally sensitive to
spontaneous apoptosis in these patients. It has been suggested that
IL-2Ra expression on a subset of T cells (CD4
+) identifies
‘regulatory’ T lymphocytes (Woo et al, 2001). In patients with
cancer, the numbers of regulatory cells are increased (Woo et al,
2001), and it is possible that they are protected from apoptosis. On
the other hand, the IL-2R/IL-2 complex is known to play a crucial
role in survival and death of T cells (Van Parijs et al, 1997). The
presence or absence of IL-2Ra on the T cell is crucial for its
response to IL-2, which may act as a growth factor or a death
cytokine depending on the cellular microenvironment (Van Parijs
et al, 1997). Prolactin, which is known to be able to modulate
functions of T lymphocytes and act in concert with IL-2 (Matera
et al, 1992) is likely to also influence their survival. It is not certain
that PRL contributes to protection of CD3
+CD25
+ lymphocytes in
vivo; however, our ex vivo experiments suggest that anti-CD3Ab-
activated CD25
+ T cells, which can bind IL-2, are in part protected
from AICD by exogenous PRL. The possible role of PRL in
protection of activated T cells from apoptosis deserves further
studies.
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